Federated Investors Inc. PA Has $1.19 Million Stake in Regeneron Pharmaceuticals Inc (REGN)

Federated Investors Inc. PA lifted its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 10.7% during the first quarter, Holdings Channel reports. The fund owned 3,456 shares of the biopharmaceutical company’s stock after purchasing an additional 334 shares during the quarter. Federated Investors Inc. PA’s holdings in Regeneron Pharmaceuticals were worth $1,190,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Canandaigua National Bank & Trust Co. purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $1,536,000. Cannell Peter B & Co. Inc. acquired a new position in Regeneron Pharmaceuticals in the first quarter worth about $337,000. Pictet & Cie Europe SA grew its stake in Regeneron Pharmaceuticals by 14.5% in the first quarter. Pictet & Cie Europe SA now owns 1,486 shares of the biopharmaceutical company’s stock worth $512,000 after purchasing an additional 188 shares in the last quarter. Sustainable Growth Advisers LP grew its stake in Regeneron Pharmaceuticals by 18.6% in the first quarter. Sustainable Growth Advisers LP now owns 1,045,910 shares of the biopharmaceutical company’s stock worth $360,169,000 after purchasing an additional 163,981 shares in the last quarter. Finally, Rockefeller Capital Management L.P. acquired a new position in Regeneron Pharmaceuticals in the first quarter worth about $61,447,000. 66.52% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ REGN opened at $309.53 on Wednesday. The company has a market cap of $33.60 billion, a PE ratio of 23.08, a price-to-earnings-growth ratio of 1.12 and a beta of 1.40. Regeneron Pharmaceuticals Inc has a 12-month low of $281.89 and a 12-month high of $543.55. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.59 and a quick ratio of 2.94.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported $4.67 EPS for the quarter, missing the consensus estimate of $5.08 by ($0.41). The business had revenue of $1.51 billion for the quarter, compared to analysts’ expectations of $1.50 billion. Regeneron Pharmaceuticals had a return on equity of 29.92% and a net margin of 23.54%. The company’s revenue was up 14.6% compared to the same quarter last year. During the same period last year, the business posted $2.92 earnings per share. analysts predict that Regeneron Pharmaceuticals Inc will post 17.2 earnings per share for the current year.

In other news, major shareholder Sanofi sold 121,601 shares of the firm’s stock in a transaction that occurred on Friday, June 8th. The shares were sold at an average price of $309.31, for a total value of $37,612,405.31. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Joseph L. Goldstein sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, March 19th. The stock was sold at an average price of $350.02, for a total transaction of $700,040.00. Following the completion of the transaction, the director now owns 14,000 shares in the company, valued at approximately $4,900,280. The disclosure for this sale can be found here. Insiders have sold 142,008 shares of company stock worth $43,675,567 over the last three months. Insiders own 12.42% of the company’s stock.

A number of equities analysts recently commented on REGN shares. BidaskClub upgraded Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, March 29th. Barclays set a $290.00 price target on Regeneron Pharmaceuticals and gave the stock a “sell” rating in a research note on Thursday, May 3rd. Credit Suisse Group set a $420.00 price target on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, April 27th. Zacks Investment Research downgraded Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 9th. Finally, BMO Capital Markets set a $361.00 price target on Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research note on Friday, May 4th. Four equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $426.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit